Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin in Newly Diagnosed Glioblastoma Multiforme
NCT00005856Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2000
- Primary completion
- Jan 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in glioblastoma multiforme (GBM), sponsored by National Cancer Institute. Primary endpoints: Maximum-tolerated dose at 14 days, Dose-limiting toxicity at 14 days and 1 more. Started Dec 2000; status: terminated.
02
Drugs
oxaliplatin
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00005856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005856.